Australia · Delayed Price · Currency is AUD Proteomics International Laboratories Company Description
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India.
It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes.
The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing.
It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre.
Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.
| Country | Australia |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Morris |
Contact Details
Address: Harry Perkins Institute of Medical Research Nedlands, Washington 6009 Australia | |
| Phone | 61 8 9389 1992 |
| Website | proteomics.com.au |
Stock Details
| Ticker Symbol | PIQ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PIQ0 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Jacqueline Gray | Head of Corporate Development |
| Timothy Luscombe B.Com., C.A. | Chief Financial Officer and Company Secretary |
| John Chuck Morrison | Head of Business Development |
| Dr. Scott Bringans | Head of Research |
| Dr. Pearl Tan | Head of Product Development |
| Dr. Kirsten Peters | Head of Clinical Studies |
| Phillip Prather | Chief Commercial Officer |